Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
Sponsor: Neurocrine Biosciences
A PHASE2 clinical study on Tourette Syndrome, this trial is completed. The trial is conducted by Neurocrine Biosciences and has accumulated 12 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Apr 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Neurocrine Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .